β-1,3-Gal-T3 Activators
β-1,3-Gal-T3 Activators are a diverse set of chemical compounds that indirectly enhance the functional activity of β-1,3-Gal-T3, primarily through the modulation of various cellular signaling pathways. Compounds such as Forskolin and Epigallocatechin gallate (EGCG) work by activating adenylate cyclase and inhibiting certain protein kinases, respectively. These actions result in the elevation of cAMP levels and the alteration of kinase signaling, indirectly promoting β-1,3-Gal-T3's role in protein and lipid glycosylation. Similarly, the PI3K inhibitor LY294002, the p38 MAPK inhibitor SB203580, and the MEK1/2 inhibitor U0126, all contribute to enhancing β-1,3-Gal-T3 activity by shifting the cellular signaling equilibrium. This shift favors pathways that enhance glycosylation processes, a key function of β-1,3-Gal-T3. Additionally, compounds like Rapamycin and Staurosporine, through mTOR inhibition and broad-spectrum kinase inhibition, respectively, indirectly augment β-1,3-Gal-T3 activity by altering cellular metabolic states and reducing competitive signaling pathways, further supporting the glycosylation role of β-1,3-Gal-T3.
The influence of β-1,3-Gal-T3 activators extends through various other mechanisms. Phorbol 12-myristate 13-acetate (PMA) and Sphingosine-1-phosphate (S1P) enhance β-1,3-Gal-T3 activity through the activation of PKC and G protein-coupled receptors, respectively. These activations lead to downstream signaling effects that enhance β-1,3-Gal-T3's involvement in glycosylation processes essential for cell communication and signal transduction. The MEK inhibitor PD98059 further contributes to this enhancement by shifting signaling towards β-1,3-Gal-T3 favorable pathways. Brefeldin A and Thapsigargin, by disrupting the Golgi apparatus and elevating intracellular calcium levels, respectively, also play a critical role. These actions indirectly enhance β-1,3-Gal-T3 activity by influencing glycosylation patterns and promoting calcium-dependent signaling pathways crucial for its function. Collectively, these β-1,3-Gal-T3 Activators, through their targeted effects on various cellular signaling mechanisms, facilitate the enhancement of β-1,3-Gal-T3 mediated glycosylation functions, crucial for maintaining cellular communication and signaling integrity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates Protein Kinase C (PKC), which influences downstream signaling including phosphorylation of substrates that enhance β-1,3-Gal-T3 activity in galactosylation of proteins and lipids. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP and activating PKA, which indirectly enhances β-1,3-Gal-T3 activity in glycoprotein interactions. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits certain protein kinases, altering signaling pathways that upregulate β-1,3-Gal-T3 activity in glycosylation processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, LY294002 alters the PI3K/Akt pathway, enhancing β-1,3-Gal-T3 activity and promoting glycosylation pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This p38 MAPK inhibitor shifts signaling to enhance β-1,3-Gal-T3 activity, increasing protein glycosylation processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2 in the MAPK/ERK pathway, indirectly upregulating β-1,3-Gal-T3 activity and promoting its role in glycosylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By inhibiting mTOR, Rapamycin enhances β-1,3-Gal-T3 activity, shifting cellular states to favor glycosylation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
As a broad-spectrum kinase inhibitor, Staurosporine indirectly enhances β-1,3-Gal-T3 activity by promoting glycosylation pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This MEK inhibitor shifts signaling towards β-1,3-Gal-T3 favorable pathways, enhancing glycosylation functions. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P activates G protein-coupled receptors, enhancing β-1,3-Gal-T3 activity in glycosylation processes. | ||||||